WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Navin Fluorine Q3 Results: Navin Fluorine International announced its results for the quarter ending December 2025 (Q3FY26) on February 2. The company posted a strong set of financial numbers, posting ...

From the moment the first photographs surfaced online, the wedding of Sahil Reddy in Chennai became more than just a family celebration. Images of former Andhra Pradesh Chief Minister Y.S. Jagan Mohan ...

Sometimes, one piece of good news is enough to change the mood completely. A delayed train finally arriving. An unexpected message. A long-pending result going your way. Markets work much the same way ...

Hyderabad: Chief minister A Revanth Reddy on Sunday began an executive education programme at Harvard University's Kennedy School in Cambridge, Massachusetts, marking a rare academic engagement by a ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

Beginning in 2026, the ACC's Distinguished Award for International Service will be named in honor of Navin C. Nanda, MD, FACC, thanks to the support of the American Association of Cardiologists of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

What are music’s biggest global artist stories of 2025? Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...